在2型糖尿病小鼠中,小麦粉-Lonicera caerulea果多复合物调节血糖,改善肠道菌群
Suwen Liu1, Fanna Meng2, Ruonan Sun2
1Engineering Research Center of Chestnut Industry Technology of Ministry of Education, College of Food Science & Technology, Hebei Normal University of Science and Technology, Qinhuangdao, Hebei 066004, China; Hebei Yanshan Special Industrial Technology Research Institute, Hebei Normal University of Science and Technology, Qinhuangdao 066004, China; Hebei Yanshan Special Fruit Processing Technology Innovation Center, Chengde 067600, China.
Carbohydrate polymers
|January 8, 2025
概括
一种新的小麦粉-Lonicera caerulea果多复合物 (WS-LCBP) 复合物有效降低了2型糖尿病小鼠的血糖和胰岛素抵抗. 这种多醇粉生物大分子为功能性食品提供了潜在的向食后高血糖的潜力.
科学领域:
- 食品科学与技术 食品科学与技术
- 生物化学 生物化学
- 营养科学 营养科学
背景情况:
- 耐性粉 (RS) 通过延迟碳水化合物消化,在管理食后血糖方面发挥着至关重要的作用.
- 开发新的以食物为基础的策略来增强RS和改善葡萄糖代谢对于管理2型糖尿病 (T2DM) 至关重要.
研究的目的:
- 使用高水静压 (HHP) 构建一个小麦粉-Lonicera caerulea果多 (WS-LCBP) 综合体.
- 研究WS-LCBP对T2DM模型小鼠血糖调节,胰岛素抵抗和肠道微生物群的影响.
主要方法:
- 一个WS-LCBP复合物使用HHP (600MPa,30分钟) 与10%的Lonicera caerulea果多 (LCBP) 合成.
- 分析了复合物的结构和耐性粉含量.
- 对T2DM小鼠进行了胃内注射WS-LCBP,并评估了对2小时食后血糖,胰岛素抵抗的恒常性模型评估 (HOMA-IR),肝脏信号通路 (西式涂抹),短链脂肪酸 (SCFA) 和肠道微生物群的影响.
主要成果:
- HHP治疗显著增加了WS-LCBP中的RS含量,从7.65%增加到49.66%,形成了阻碍葡萄糖释放的A+V型晶体结构.
- 与单独使用LCBP相比,WS-LCBP的使用导致HOMA-IR下降35.3%,食后2小时血糖降低8.3%.
- WS-LCBP激活了肝脏中的GLP-1R/PI3K/AKT信号通路,增加了SCFA度,改善了肠道微生物群的结构和丰富性.
结论:
- WS-LCBP复合物通过增强耐性粉的形成和调节肠道微生物群,有效地改善T2DM小鼠的葡萄糖代谢和胰岛素敏感性.
- 这种多醇粉复合物代表了一种有前途的功能性生物宏分子,用于开发粉含量的食物,以控制食后血糖水平.
相关概念视频
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
152
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
152
Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166


